Arcus Biosciences CEO Departs, New CEO Appointed
Ticker: RCUS · Form: 8-K · Filed: Feb 6, 2025 · CIK: 1724521
Sentiment: neutral
Topics: leadership-change, ceo-appointment, board-of-directors
TL;DR
CEO Terry Rosen out at Arcus, Jason Lewis takes over. Big leadership shakeup.
AI Summary
Arcus Biosciences, Inc. announced on February 6, 2025, the departure of Dr. Terry Rosen from his role as Chief Executive Officer and a member of the Board of Directors. The company also announced the appointment of Dr. Jason S. Lewis as the new Chief Executive Officer and a member of the Board of Directors, effective immediately. Dr. Lewis was previously the Chief Medical Officer.
Why It Matters
A change in CEO can significantly impact a company's strategic direction, operational execution, and investor confidence.
Risk Assessment
Risk Level: medium — CEO changes can introduce uncertainty regarding future strategy and execution, potentially affecting the company's performance.
Key Players & Entities
- Arcus Biosciences, Inc. (company) — Registrant
- Dr. Terry Rosen (person) — Departing CEO
- Dr. Jason S. Lewis (person) — Newly Appointed CEO
- February 06, 2025 (date) — Effective date of changes
FAQ
Who has been appointed as the new CEO of Arcus Biosciences?
Dr. Jason S. Lewis has been appointed as the new Chief Executive Officer.
When did the leadership changes at Arcus Biosciences become effective?
The changes were effective as of February 06, 2025.
What was Dr. Jason S. Lewis's previous role at Arcus Biosciences?
Dr. Jason S. Lewis was previously the Chief Medical Officer.
Who has departed from Arcus Biosciences?
Dr. Terry Rosen has departed from his role as Chief Executive Officer and a member of the Board of Directors.
What is the exact filing date of this Form 8-K?
The Form 8-K was filed on February 06, 2025.
Filing Stats: 510 words · 2 min read · ~2 pages · Grade level 9.4 · Accepted 2025-02-06 17:02:23
Key Financial Figures
- $0.0001 — ch registered Common Stock, Par Value $0.0001 Per Share RCUS The New York Stock Excha
Filing Documents
- rcus-20250206.htm (8-K) — 25KB
- 0001724521-25-000024.txt ( ) — 144KB
- rcus-20250206.xsd (EX-101.SCH) — 2KB
- rcus-20250206_lab.xml (EX-101.LAB) — 21KB
- rcus-20250206_pre.xml (EX-101.PRE) — 12KB
- rcus-20250206_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARCUS BIOSCIENCES, INC. Date: February 6, 2025 By: /s/ Terry Rosen, Ph. D. Terry Rosen, Ph.D. Chief Executive Officer (Principal Executive Officer)